Literature DB >> 19170216

"End-stage" pulmonary fibrosis in sarcoidosis.

Alvin T Teirstein1, Adam S Morgenthau.   

Abstract

Pulmonary fibrosis is an unusual "end stage" in patients with sarcoidosis. Fibrosis occurs in a minority of patients, and presents with a unique physiologic combination of airways dysfunction (obstruction) superimposed on the more common restrictive dysfunction. Imagin techniques are essential to the diagnosis, assessment and treatment of pulmonary fibrosis. Standard chest radiographs and CT scans may reveal streaks, bullae, cephalad retraction of the hilar areas, deviation of the trachea and tented diaphragm. Positive gallium and PET scans indicate residual reversible granulomatous disease and are important guides to therapy decisions. Treatment, usually with corticosteroids, is effective in those patients with positive scans, but fibrosis does not improve with any treatment. With severe functional impariment and patient disability, pulmonary hypertension and right heart failure may supervene for which the patient will require treatment. Oxygen, careful diuresis, sildenafil and bosentan may be salutary. These patients are candidates for lung transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 19170216     DOI: 10.1002/msj.20090

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  7 in total

Review 1.  Translating tissue-engineered tracheal replacement from bench to bedside.

Authors:  Madhuri Kalathur; Silvia Baiguera; Paolo Macchiarini
Journal:  Cell Mol Life Sci       Date:  2010-08-21       Impact factor: 9.261

2.  The clinical and immunologic features of pulmonary fibrosis in sarcoidosis.

Authors:  Karen C Patterson; Kyle Hogarth; Aliya N Husain; Anne I Sperling; Timothy B Niewold
Journal:  Transl Res       Date:  2012-04-10       Impact factor: 7.012

3.  Cardiac Involvement in Sarcoidosis Deaths in Wayne County, Michigan: A 20-Year Retrospective Study.

Authors:  Milad Webb; Kyle S Conway; Martin Ishikawa; Francisco Diaz
Journal:  Acad Forensic Pathol       Date:  2018-08-31

4.  A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.

Authors:  Rémy L M Mostard; Sander M J Van Kuijk; Johny A Verschakelen; Marinus J P G van Kroonenburgh; Patty J Nelemans; Petal A H M Wijnen; Marjolein Drent
Journal:  BMC Pulm Med       Date:  2012-09-14       Impact factor: 3.317

Review 5.  Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): A New Phenotype or a Fortuitous Overlap? Scoping Review and Case Series.

Authors:  Laura Bergantini; Gabriele Nardelli; Miriana d'Alessandro; Giusy Montuori; Caterina Piccioli; Elisabetta Rosi; Sara Gangi; Dalila Cavallaro; Paolo Cameli; Elena Bargagli
Journal:  J Clin Med       Date:  2022-04-06       Impact factor: 4.241

Review 6.  Sarcoidosis: Progression to the chronic stage and pathogenic based treatment (narrative review).

Authors:  Anna Malkova; Yulia Zinchenko; Anna Starshinova; Dmitriy Kudlay; Igor Kudryavtsev; Anzhela Glushkova; Piotr Yablonskiy; Yehuda Shoenfeld
Journal:  Front Med (Lausanne)       Date:  2022-09-06

Review 7.  Annexins family: insights into their functions and potential role in pathogenesis of sarcoidosis.

Authors:  Mehdi Mirsaeidi; Sanaz Gidfar; Ann Vu; Dean Schraufnagel
Journal:  J Transl Med       Date:  2016-04-12       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.